眼科学領域におけるCefuroxime axetil (CXM-AX) の臨床的・基礎的検討

DOI

書誌事項

タイトル別名
  • THE CLINICAL EXPERIMENT OF CEFUROXIME AXETIL (CXM-AX) IN EXTERNAL EYE DISEASES AND THE PENETRATION INTO THE TEAR OF HUMAN EYES

抄録

Cefuroxime axetil (CXM-AX, SN 407), a new oral cephalosporin antibiotic, was administered to a total of 28 patients, i. e. 7 patients with hordeolum and 21 patients with meibomitis, to evaluate its clinical efficacy. 250 mg or 500 mg CXM-AX was given after meal three times a day, and the duration of administration ranged 2-12 days. The clinical efficacy was excellent in 16 patients, good in 11 and fair in 1, the efficacy rate being 96.4%. As for adverse events, gastric discomfort was observed in one patient, and diarrhea in another. They were, however, mild and rapidly disappeared on the next day of withdrawal of CXM-AX.<BR>After a single dose of 250 mg CXM-AX given after meal to healthy volunteers, CXM levels in tear and serum were determined. The peaks of CXM levels in tear were achieved at about 2 hrs after dosing, and the mean peak level was 0.33 μg/ml, which corresponded to about 10% of mean serum level of 3.10 μg/ml obtained at the time.<BR>The ratio of concentrations in tear to those in serum was similar to that of cephalexin, another cephalosporin.

収録刊行物

詳細情報 詳細情報について

問題の指摘

ページトップへ